Clinical Trials - August 16, 2016
Moberg Pharma starts new trial
Moberg Pharma has announced that the U.S. Food and Drug Administration (FDA) has approved the Company’s Investigational New Drug (IND) application and that a No Objection Letter has been received from Health Canada to begin its Phase 3 trial for MOB-015 in the treatment of onychomycosis. This allows Moberg Pharma to start enrolling patients in the […]
Pharma Business - January 26, 2016
Moberg Pharma issues a bond loan
Moberg Pharma announces that the company has decided to issue a five-year senior unsecured bond loan in the amount of SEK 300 million with maturity on January 29th, 2021. The bond loan will give a floating rate coupon of Stibor 3m + 6.00% and have a total framework amount of SEK 600 million. Moberg Pharma intends […]
Agreement - November 5, 2015
Moberg Pharma, Colep enter agreement
Moberg Pharma and Colep have entered a development agreement for MOB-015, a novel topical formulation of terbinafine for onychomycosis (nail fungus). Under the agreement, Colep’s Healthcare Division will share funding by conducting a pharmaceutical development program which will include scale-up of manufacturing processes, stability programs and supply of clinical trial material for the Phase 3 […]
Intellectual Property - April 2, 2015
Patent for Nail Fungus Drug
The European Patent Office has issued a patent for Moberg PharmaAB’s topical treatment MOB-015 for onychomycosis (toenail fungus). The patent is expected to be in effect until 2032. Moberg Pharma reported positive results last September from a Phase II study of MOB-015 and in January 2015, received similar patent approval in the U.S. “The granted […]
Collaboration - November 4, 2014
Moberg Pharma expands partnership with Emerson Group
Moberg Pharma has entered into a services agreement with Emerson Healthcare, a division of Emerson Group, who will provide certain logistical services and all order to cash functions for retailer and wholesaler customers in the U.S. Along with the outsourcing agreement, the companies are entering into a new Sales Representation Agreement with Emerson Group. […]
Clinical Trials - October 29, 2014
Moberg Pharma enters Phase II
Moberg Pharma announced that the first patient has been included in a randomized controlled phase II study with BUPI, a novel topical formulation for the treatment of oral pain. The aim is to confirm the promising results gained from several smaller pilot studies and to evaluate if bupivacaine formulated as a lozenge can be an […]
